Moreover, we observed that the ECM is actively remodeled both in MCs and RPCs under diabetic conditions, and we identified the key ECM remodeling molecule Col11a1 in DN, which could probably serve as a new biomarker for altered ECM remodeling and provide exciting possibilities for therapeutic intervention. This evidence concerns the gene COL11A1 and liver dysplastic nodule.